Warning Letter — Medica Weight Loss
The FDA issued a warning letter to Medica Weight Loss on June 8, 2026, centering on findings from the Center for Drug Evaluation and Research regarding the company's marketing practices.
This action affects Medica Weight Loss and its internal departments responsible for product labeling, digital marketing, and regulatory compliance for weight management products.
While the source provides limited detail on specific product ingredients, the involvement of CDER suggests that the company's products or claims likely crossed the threshold from supplements or general wellness into unapproved drug territory. Regulatory professionals should interpret this as continued FDA scrutiny of the weight loss sector, particularly regarding claims that imply a product can treat or mitigate obesity or related conditions without prior drug approval.
Regulatory and marketing teams should conduct an immediate audit of all digital footprints, including social media and website claims, to ensure weight loss products are not being marketed as unapproved new drugs. QA should verify that any product making therapeutic claims has the requisite FDA approval or falls strictly within supplement labeling requirements.
FDA Warning Letter issued to: Medica Weight Loss. 06/08/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medica-weight-loss-728284-06082026
Open in openFDA / FDA.gov